TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01351597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel/ oxaliplatin
Description: 1. docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~2. oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks
Study: NCT04787692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid and Benzodiazepine Naive-patients
Description: Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid and Benzodiazepine Tolerant-patients
Description: Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
Study: NCT01648491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Biopsy of thigh muscle to obtain stem cell core.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous stem cells
Description: After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
Study: NCT03345199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Trainer (IMT)
Description: During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
Study: NCT00036868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMF regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT03779776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin AD
Description: In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
Study: NCT00894621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01726582

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 2: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 3: Targeted chemotherapy prior to surgery
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 3: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
Description: A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
Study: NCT03258411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Expansion of palatal suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Expansion of palatal suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Expansion of palatal suture
Study: NCT01138709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitala
Description: Vitala™ Continence Control Device
Study: NCT01726582

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 4: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study: NCT02501616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Study: NCT01704482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
Study: NCT04512664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: cold application with gel pacs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cold application
Description: cold application with gel pacs
Study: NCT00324987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01704482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00494572

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sterile water
Description: sterile water
Study: NCT04150224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 640 mg OD
Description: Two administrations once a day with a wash-out period: food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 640 mg OD
Description: Two administrations once a day with a wash-out period: food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 640 mg BiD
Description: Twice a day fasted; 1 day of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 960 mg SD
Description: Once a day fasted
Study: NCT02501616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Study: NCT02299011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro drug eluting stent
Description: Orsiro Hybrid drug eluting stent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix Flex drug eluting stent
Study: NCT04277273

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaires WHOQOL-BREF and GOHAI
Study: NCT03056170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real tDCS
Description: In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code.
Study: NCT03839355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Dosage either 5mg or 2.5mg for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dosage assessed by your treating physician for 2 years
Study: NCT01840124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of fibroids
Description: The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
Study: NCT02033343

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate cancer radiotherapy using real-time tracking
Description: Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
Study: NCT00084825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 600 mg orally daily
Study: NCT01995253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy expenditure estimation in controlled conditions
Description: Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy expenditure estimation in free-living conditions
Description: Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
Study: NCT02475109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution
Study: NCT00855634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of metastases
Description: resection of the primary tumor, followed by resection of the liver metastasis/metastases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of infiltrated veins
Description: resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
Study: NCT01773434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-004
Description: MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1.
Study: NCT01813682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment group1
Description: fe-1 group with TPN of iron supplementation of 200μg/kg/d.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment group2
Description: fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
Study: NCT02652676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reversible Pulmonary Artery Banding
Description: A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GORE-TEX DualMesh EMERGE PLUS Biomaterial
Description: The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
Study: NCT04063748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiological rehabilitation
Description: Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo Rehabilitation
Description: CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive Control
Description: No intervention in the passive control group for HA-users.
Study: NCT03378024

Intervention type: DEVICE
Intervention: oscillometric (Omron Colin co)
Description: fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
Study: NCT01164631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioajusta X Orthodontic treatment
Description: Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
Study: NCT01297738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal size increase with HFHS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
Study: NCT00324987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01726582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 5: Targeted chemotherapy after surgery
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 5: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 6: Gemcitabine after surgery
Description: Chemotherapy treatment with Gemcitabine.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 6: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 7: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 8: Targeted chemotherapy after surgery
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 9: Gemcitabine after surgery
Description: Chemotherapy treatment with Gemcitabine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milestone 10: No additional therapy after surgery
Description: The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
Study: NCT00241345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Study: NCT04548856

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microsurgical clipping
Description: Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microsurgical clipping
Description: Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular embolization
Description: Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular embolization
Description: Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
Study: NCT04150224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 1280 mg SD
Description: Once a day fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 1280 mg MD
Description: Once a day after meal, 14 doses
Study: NCT01617603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa Polyphenols
Description: 20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Polyphenols
Description: 20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Polyphenols
Description: 20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
Study: NCT03750981

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12 week pilot intervention study.
Description: Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
Study: NCT03771833

Intervention type: DEVICE
Group type: OTHER
Intervention: MARIA scan
Description: The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.

Intervention type: DEVICE
Group type: OTHER
Intervention: MARIA scan
Description: The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
Study: NCT00832351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilisation
Description: Mobilisation
Study: NCT00064246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study: NCT04213898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+Albumin-bound paclitaxel + epirubicin
Description: Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
Study: NCT02134457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study: NCT00874068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InFat™ based infant formula
Description: high sn-2 palmitic acid oil based infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vegetable oil based infant formula
Description: standard vegetable oil based infant formula